Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Berk

Showing results (341-350 of 398) with videos related to

Pageof 40
Sort By:
JACC. Heart Failure|December 14, 2020
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACTClaudio Rapezzi, Perry Elliott, Thibaud Damy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxelC Sessa, D Tosi, L Viganò, et al.
The New England Journal of Medicine|December 24, 1998
The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study ConsortiumS A Bozzette, S H Berry, N Duan, et al.
International Journal of Radiation Oncology, Biology, Physics|October 20, 2001
Radiation Therapy Oncology Group. Research Plan 2002-2006. Outcomes CommitteeD Watkins Bruner, L Berk, M Bondy, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 2, 2022
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosisYukio Ando, David Adams, Merrill D Benson, et al.
Clinical Lymphoma|April 4, 2003
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosisDavid C Seldin, Elie B Choufani, Laura M Dember, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 28, 2025
Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosisJonas Wixner, Isabel Conceição, John L Berk, et al.
Acta Neuropsychiatrica|July 12, 2016
05-03 Disease burden of bipolar and schizoaffective disorder in an Australian cohortA R de Castella, M Berk, P Fitzgerald, et al.
Orphanet Journal of Rare Diseases|July 10, 2020
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosisTeresa Coelho, David Adams, Isabel Conceição, et al.
Blood|June 20, 1998
Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patientsR L Comenzo, E Vosburgh, R H Falk, et al.
Pageof 40

Showing results (341-350 of 398) with videos related to

Sort By:
Pageof 40
JACC. Heart Failure|December 14, 2020
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACTClaudio Rapezzi, Perry Elliott, Thibaud Damy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxelC Sessa, D Tosi, L Viganò, et al.
The New England Journal of Medicine|December 24, 1998
The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study ConsortiumS A Bozzette, S H Berry, N Duan, et al.
International Journal of Radiation Oncology, Biology, Physics|October 20, 2001
Radiation Therapy Oncology Group. Research Plan 2002-2006. Outcomes CommitteeD Watkins Bruner, L Berk, M Bondy, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 2, 2022
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosisYukio Ando, David Adams, Merrill D Benson, et al.
Clinical Lymphoma|April 4, 2003
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosisDavid C Seldin, Elie B Choufani, Laura M Dember, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 28, 2025
Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosisJonas Wixner, Isabel Conceição, John L Berk, et al.
Acta Neuropsychiatrica|July 12, 2016
05-03 Disease burden of bipolar and schizoaffective disorder in an Australian cohortA R de Castella, M Berk, P Fitzgerald, et al.
Orphanet Journal of Rare Diseases|July 10, 2020
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosisTeresa Coelho, David Adams, Isabel Conceição, et al.
Blood|June 20, 1998
Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patientsR L Comenzo, E Vosburgh, R H Falk, et al.
Pageof 40